Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Laureate To Produce Lpath Antibody for Phase I Trials | Contract Pharma

What are you searching for?

Sign in
Breaking News

Laureate To Produce Lpath Antibody for Phase I Trials

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lpath, Inc. and Laureate Pharma have entered into an agreement for the production of recombinant Sphingomab, Lpath’s humanized monoclonal antibody specific for sphingosine-1-phosphate (S1P). It is designed for use as a potential therapeutic for diseases like cancer and various ocular and cardiovascular conditions. Laureate will provide cell line development, optimization, and upstream and downstream process development, followed by cGMP manufacture of the product for use in clinical trials.

“Lpath has developed an impressive and unmatched ability to generate monoclonal antibodies against bioactive lipids,” notes Robert J. Broeze, Ph.D., president and chief executive officer of Laureate Pharma. “We are excited Lpath has chosen Laureate Pharma to design and implement a manufacturing process that will make this medical breakthrough available for clinical trials.”

Dr. Bill Garland, Lpath’s vice president of preclinical development, commented, “Given Laureate’s decades of experience producing monoclonal- antibody therapeutics and their state-of-the-art facilities, Laureate Pharma was a compelling choice for Lpath and a great fit with our manufacturing strategy.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics